SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
August 2015
Commission File Number 1-15182
DR. REDDYS LABORATORIES LIMITED
(Translation of registrants name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If Yes is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82- .
EXHIBITS
Exhibit |
Description of Exhibits | |
99.1 | Press Release, Dr. Reddys announces the Launch of Memantine Hydrochloride Tablets, USP, July 13, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDYS LABORATORIES LIMITED (Registrant) | ||||||||
Date: August 24, 2015 | By: | /s/ Sandeep Poddar | ||||||
Name: | Sandeep Poddar | |||||||
Title: | Company Secretary |
Exhibit 99.1
DR. REDDYS LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. |
CONTACT | |||
INVESTOR RELATIONS | MEDIA RELATIONS | |||
KEDAR UPADHYE kedaru@drreddys.com |
CALVIN PRINTER calvinprinter@drreddys.com | |||
(Ph: +91-40-66834297) | (Ph: +91-40- 49002121) |
Dr. Reddys announces the Launch of MEMANTINE HYDROCHLORIDE TABLETS, USP
Hyderabad, India, July 13, 2015
Dr. Reddys Laboratories (NYSE: RDY) announced today that it has launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic version of NAMENDA® (memantine HCl) tablets in the US market on July 12, 2015 approved by the United States Food & Drug Administration (USFDA).
The NAMENDA® (memantine HCl) tablets brand had U.S. sales of approximately $ 1.4 Billion MAT for the most recent twelve months ending in May 2015 according to IMS Health*.
Dr. Reddys Memantine hydrochloride tablets USP, 5 mg is available in bottle count size of 60 and the Memantine hydrochloride tablets USP, 10 mg are available in bottle count sizes of 60 and 500.
NAMENDA® is a registered trademark of Merz Pharma GmbH & Co. KGaA
* | IMS National Sales Perspectives: Retail and Non-Retail MAT May 2015 |
About Dr. Reddys: Dr. Reddys Laboratories Ltd. is an integrated pharmaceutical company, committed to accelerating access to affordable and innovative medicines, because it believes Good Health Cant Wait. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products the company offers a portfolio of products and services that include active pharmaceutical ingredients, (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. With operations in 26 countries across the globe, the major therapeutic areas of Dr. Reddys are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the managements current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential, or continue and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.
The company assumes no obligation to update any information contained herein.
;\L>,N-Y!^*SV=QEKDXS1\3I@7L/L]K [:[W:ZA'J%0DO[*%Y9+*QKQZ5U7
M4.YN/V\^.M@957?.H]@:AL,FR/(Q<;?:V_@C2S!(4RKO(=VX3&/EV[8RQ"K&
M;+*@@8Y2J>IA ,R#CG+.,GVD5_)29[H=94O<_*;I]U5L:.1F:)>.5%XB;7"N3>K6;B$:
M]3I5:#>!_M&,TK'$:+I_[5%8Q/\ 2S#/IPS>2XYP;R%G<.\QY2UP4+XGCJQY
MDF:'C_B8'%S3Z. /HK;#ROAMKN6/1[8A3[-3K^"E7V-[UG] +:"AZ7SMXW\$
M(==Y+O%HO